“We expect upside from COVID-19 testing, plus organic growth in our base Diagnostics and Surgical businesses, to offset headwinds from supply chain challenges in our Breast Health business,” CFO Karleen Oberton said in a news release.
Get the full story at our sister site, Medical Design & Outsourcing.
Mary J. Blige will star in Hologic’s first nationwide ad campaign for consumers. [Photo courtesy of Hologic]
Hologic (NSDQ:HOLX) posted fiscal first-quarter results today that beat the consensus forecast on Wall Street and increased its outlook for the rest of the year.“We expect upside from COVID-19 testing, plus organic growth in our base Diagnostics and Surgical businesses, to offset headwinds from supply chain challenges in our Breast Health business,” CFO Karleen Oberton said in a news release.
Marlborough, Massachusetts–based Hologic reported profits of $499.2 million, or $1.95 per diluted share, on sales of $1.47 billion for the three months ended Dec. 25, 2021, for a bottom-line decrease of 23.7% and an 8.6% decrease in sales compared with the prior-year quarter.
“In our first quarter of fiscal 2022, excluding COVID-19, we delivered robust revenue growth across all of ou…
Hologic (NSDQ:HOLX) announced today that it completed regulatory steps allowing it to make Panther Trax available across a number of geographies.
Marlborough, Massachusetts-based Hologic’s launch of Panther Trax offers a new addition to its Panther scalable solutions (PSS) portfolio of products, enhancing lab automation through the physical linking of multiple Panther instruments into a single workcell that allows for an increase in testing volumes without increasing staff.
According to a news release, Panther Trax holds the listing of a Class I medical device with the FDA and has CE mark approval in Europe. It will also be available commercially in Canada, Australia and New Zealand, Hologic said.
Panther Trax offers full automation to meet high-volume testing demands, allowing labs to customize configuration to meet space constraints and minimize facility costs.
“Clinical laboratories have performed heroically, meeting unprecedented demand …
Several medtech, healthcare and life sciences companies, including big names like Abbott (NYSE:ABT), 3M (NYSE:MMM) and Baxter (NYSE:BAX), are among the 500 “most responsible,” according to Newsweek.
The outlet published its “America’s Most Responsible Companies 2022” list, marking the third installment of the compilation (in partnership with Statista), this time expanded to include 500 of the largest public corporations around. Companies were judged with an overall score out of 100 that combined environmental, social and corporate governance performance assessments.
Baxter, 3M, Abbott and BD (NYSE:BDX) were among the highest-ranking big-name medical device makers. Cancer diagnostic company Illumina was the highest-ranking company under the healthcare and life sciences umbrella, sitting in second behind HP.
In sixth sat Baxter, registering an overall score of 89.5 points, with its highest performance coming in environmental i…
Acting FDA Commissioner Dr. Janet Woodcock
Acting FDA Commissioner Dr. Janet Woodcock thinks many COVID-19 tests will continue to work with the new Omicron variant — with information coming soon on vaccine efficacy.
In a statement posted yesterday, Woodcock said she thought the agency is well-positioned to work with companies to address the potential impact of viral mutations on COVID-19 tests, therapeutics, and vaccines.
“Getting vaccinated or receiving a booster with one of the currently available vaccines is the best thing that you can do right now (in addition to standard precautions like wearing a mask) to help protect yourself, your family and friends,” Woodcock said.
Discovered in late November in South Africa, the Omicron variant has more than 30 changes to the SARS-CoV-2 spike protein. The variant has enough mutations to raise concerns worldwide, even though it is still un…
Hologic (NSDQ:HOLX) announced today that it closed its previously announced $160 million purchase of Bolder Surgical.
Marlborough, Massachusetts-based Hologic said just last month that it agreed to a deal that would see it acquire Louisville, Colorado-based developer and manufacturer of advanced energy vessel-sealing surgical devices.
According to a news release, Hologic’s acquisition of Bolder adds laparoscopic vessel sealing, dividing and dissecting devices to its surgical portfolio. Additionally, the company said the transaction enables it to expand Bolder’s devices to OB/GYN specialists.
Through the acquisition, all of Bolder’s devices — including the CoolSeal vessel sealing suite, JustRight 3mm vessel sealer and JustRight 5mm stapler — will join Hologic’s surgical portfolio.
“The acquisition of Bolder Surgical will expand Hologic’s growing laparoscopic portfolio and underscores our commitment to women’…
Discovered last week in South Africa, the new variant has enough mutations that it has raised concerns worldwide — even though it is still unknown for sure whether the mutations cause greater transmissibility or vaccine evasion. The United States is among the countries restricting travel from southern Africa for the time being, and the CDC is advising all adults to get a booster shot.
Get the full story on our sister site Medical Design & Outsourcing.
[Image from Pixabay]
Abbott, BD, Hologic, PerkinElmer and Thermo Fisher are reassuring the public that their COVID-19 tests detect the Omnicron variant.Discovered last week in South Africa, the new variant has enough mutations that it has raised concerns worldwide — even though it is still unknown for sure whether the mutations cause greater transmissibility or vaccine evasion. The United States is among the countries restricting travel from southern Africa for the time being, and the CDC is advising all adults to get a booster shot.
Pfizer and Moderna say they’ll create new versions of their vaccines if needed.
Abbott said in a statement on November 27: “We have already conducted an assessment of the Omicron variant, and we’re confident our rapid and PCR tests can detect the virus. While the Omicron variant contains mutations to the spike protein, Abbott’s rapid and molec…
Hologic (NSDQ:HOLX) announced today that it closed its previously announced $160 million purchase of Bolder Surgical.
Marlborough, Massachusetts-based Hologic said just last month that it agreed to a deal that would see it acquire Louisville, Colorado-based developer and manufacturer of advanced energy vessel-sealing surgical devices.
According to a news release, Hologic’s acquisition of Bolder adds laparoscopic vessel sealing, dividing and dissecting devices to its surgical portfolio. Additionally, the company said the transaction enables it to expand the use of Bolder’s devices to OB/GYN specialists.
Through the acquisition, all of Bolder’s devices — including the CoolSeal vessel sealing suite, JustRight 3mm vessel sealer and JustRight 5mm stapler — will join Hologic’s surgical portfolio.
“The acquisition of Bolder Surgical will expand Hologic’s growing laparoscopic portfolio and underscores our commitment to …
Nearly half a trillion dollars — $421 billion to be exact — that’s how much the world’s 100 largest medical device companies brought in over the past year amid the COVID-19 pandemic.
That’s one of the big takeaways from the Big 100, MassDevice and Medical Design & Outsourcing‘s annual analysis of the worlds’ 100 largest medtech companies. (Check out the full Big 100 rankings here.)
Aggregate revenue for approximately 100 of the largest medical technology companies dropped 1.2% in 2020 compared to 2019. But that’s not bad considering that the worst pandemic in a century was taking place, sparking a global recession in its wake.
Some medtech businesses that played critical roles fighting the pandemic — such as 3M’s Health Care segment and Hologic — even saw revenues increase and rose in the Big 100 rankings as a result.
Check out the full Big 100 rankings here>>Nearly half a trillion dollars — $421 billion to be exact — that’s how much the world’s 100 largest medical device companies brought in over the past year amid the COVID-19 pandemic.
That’s one of the big takeaways from the Big 100, MassDevice and Medical Design & Outsourcing‘s annual analysis of the worlds’ 100 largest medtech companies. (Check out the full Big 100 rankings here.)
Aggregate revenue for approximately 100 of the largest medical technology companies dropped 1.2% in 2020 compared to 2019. But that’s not bad considering that the worst pandemic in a century was taking place, sparking a global recession in its wake.
Some medtech businesses that played critical roles fighting the pandemic — such as 3M’s Health Care segment and Hologic — even saw revenues increase and rose in the Big 100 rankings as a result.
Check out the full Big 100 rankings here>>
Hologic (NSDQ:HOLX) posted fourth-quarter results today that handily beat the consensus forecast on Wall Street, concluding an impressive year of growth on the back of robust COVID-19 testing revenue.
The Marlborough, Massachusetts–based diagnostics and women’s health company reported quarterly profits of $328.8 million — or $1.28 per diluted share — on sales of nearly $1.32 billion for the three-month period ended Sept. 25, 2021.
Get the full story at our sister site, MassDevice.